Billiontoone, Inc. (NASDAQ:BLLN – Get Free Report) SVP Bosch John Roderick Ten sold 1,416 shares of Billiontoone stock in a transaction on Wednesday, September 9th. The shares were sold at an average price of $97.54, for a total transaction of $138,116.64. Following the transaction, the senior vice president owned 25,051 shares in the company, valued at approximately $2,443,474.54. This trade represents a 5.35% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Bosch John Roderick Ten also recently made the following trade(s):
- On Tuesday, August 25th, Bosch John Roderick Ten sold 1,417 shares of Billiontoone stock. The stock was sold at an average price of $100.00, for a total value of $141,700.00.
- On Monday, August 10th, Bosch John Roderick Ten sold 1,417 shares of Billiontoone stock. The shares were sold at an average price of $92.86, for a total value of $131,582.62.
- On Monday, June 29th, Bosch John Roderick Ten sold 1,416 shares of Billiontoone stock. The stock was sold at an average price of $120.00, for a total value of $169,920.00.
- On Monday, June 15th, Bosch John Roderick Ten sold 2,832 shares of Billiontoone stock. The stock was sold at an average price of $101.47, for a total value of $287,363.04.
Billiontoone Price Performance
BLLN traded up $0.26 on Friday, hitting $98.77. 406,007 shares of the company’s stock traded hands, compared to its average volume of 543,328. The company’s 50 day simple moving average is $112.07 and its 200-day simple moving average is $95.79. The firm has a market cap of $4.66 billion and a price-to-earnings ratio of 141.10. Billiontoone, Inc. has a one year low of $61.96 and a one year high of $150.44. The company has a current ratio of 11.69, a quick ratio of 11.31 and a debt-to-equity ratio of 0.17.
Wall Street Analyst Weigh In
Several research firms recently weighed in on BLLN. Canaccord Genuity Group assumed coverage on shares of Billiontoone in a research note on Wednesday, September 2nd. They set a “buy” rating and a $120.00 target price for the company. JPMorgan Chase & Co. cut their price target on Billiontoone from $145.00 to $130.00 and set an “overweight” rating for the company in a report on Thursday, August 6th. Wall Street Zen downgraded Billiontoone from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. BTIG Research cut their target price on shares of Billiontoone from $142.00 to $130.00 and set a “buy” rating for the company in a report on Thursday, August 6th. Finally, Weiss Ratings upgraded shares of Billiontoone from a “sell (d)” rating to a “sell (d+)” rating in a report on Tuesday, June 23rd. Seven equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $125.88.
Check Out Our Latest Stock Report on BLLN
Institutional Trading of Billiontoone
Several institutional investors and hedge funds have recently modified their holdings of the stock. Integrated Wealth Concepts LLC bought a new position in Billiontoone in the second quarter worth approximately $29,000. Rossby Financial LCC purchased a new stake in shares of Billiontoone in the 4th quarter worth $25,000. MCF Advisors LLC lifted its holdings in shares of Billiontoone by 330.8% in the 2nd quarter. MCF Advisors LLC now owns 448 shares of the company’s stock worth $54,000 after buying an additional 344 shares during the period. Wells Fargo & Company MN bought a new position in shares of Billiontoone during the 4th quarter worth $76,000. Finally, Smartleaf Asset Management LLC bought a new position in shares of Billiontoone during the 4th quarter worth $80,000.
About Billiontoone
BillionToOne, Inc is a molecular diagnostics company that develops blood-based tests designed to provide genetic and health information from small amounts of biological material. The company’s technology uses its proprietary quantitative counting template approach to improve the accuracy and sensitivity of molecular testing.
The company’s primary offerings include UNITY, a portfolio of prenatal genetic tests. These services support screening for chromosomal conditions, single-gene disorders and carrier status, and are designed to help healthcare providers assess fetal and maternal genetic risks using a maternal blood sample.
Further Reading
- Five stocks we like better than Billiontoone
- Block Makes a Federal Trust Bank Move That Could Reshape Its Fintech Model
- Kroger’s Textbook Entry for Buy-and-Hold Investors
- AST SpaceMobile Looks to Extend Its 30-Day FCC Satellite Testing Window
- Amgen Drops 10% on a Trial It Didn’t Even Run
Receive News & Ratings for Billiontoone Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Billiontoone and related companies with MarketBeat.com's FREE daily email newsletter.
